Antibodies to SARS-CoV-2 and risk of past or future sick leave

Abstract The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joakim Dillner, K. Miriam Elfström, Jonas Blomqvist, Carina Eklund, Camilla Lagheden, Sara Nordqvist-Kleppe, Cecilia Hellström, Jennie Olofsson, Eni Andersson, August Jernbom Falk, Sofia Bergström, Emilie Hultin, Elisa Pin, Anna Månberg, Peter Nilsson, My Hedhammar, Sophia Hober, Johan Mattsson, Laila Sara Arroyo Mühr, Kalle Conneryd Lundgren
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a12aa03869c945dba2214b88c4d4805c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a12aa03869c945dba2214b88c4d4805c
record_format	dspace
spelling	oai:doaj.org-article:a12aa03869c945dba2214b88c4d4805c2021-12-02T13:34:58ZAntibodies to SARS-CoV-2 and risk of past or future sick leave10.1038/s41598-021-84356-w2045-2322https://doaj.org/article/a12aa03869c945dba2214b88c4d4805c2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84356-whttps://doaj.org/toc/2045-2322Abstract The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered sick leave. For consenting 12,928 healthy hospital employees antibodies to SARS-CoV-2 could be determined and compared to participant sick leave records. Subjects with viral serum antibodies were not at excess risk for future sick leave (adjusted odds ratio (OR) controlling for age and sex: 0.85 [95% confidence interval (CI) (0.85 (0.43–1.68)]. By contrast, subjects with antibodies had an excess risk for sick leave in the weeks prior to testing [adjusted OR in multivariate analysis: 3.34 (2.98–3.74)]. Thus, presence of viral antibodies marks past disease and protection against excess risk of future disease. Knowledge of whether exposed subjects have had disease in the past or are at risk for future disease is essential for planning of control measures. Trial registration: First registered on 02/06/20, ClinicalTrials.gov NCT04411576.Joakim DillnerK. Miriam ElfströmJonas BlomqvistCarina EklundCamilla LaghedenSara Nordqvist-KleppeCecilia HellströmJennie OlofssonEni AnderssonAugust Jernbom FalkSofia BergströmEmilie HultinElisa PinAnna MånbergPeter NilssonMy HedhammarSophia HoberJohan MattssonLaila Sara Arroyo MührKalle Conneryd LundgrenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Joakim Dillner K. Miriam Elfström Jonas Blomqvist Carina Eklund Camilla Lagheden Sara Nordqvist-Kleppe Cecilia Hellström Jennie Olofsson Eni Andersson August Jernbom Falk Sofia Bergström Emilie Hultin Elisa Pin Anna Månberg Peter Nilsson My Hedhammar Sophia Hober Johan Mattsson Laila Sara Arroyo Mühr Kalle Conneryd Lundgren Antibodies to SARS-CoV-2 and risk of past or future sick leave
description	Abstract The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered sick leave. For consenting 12,928 healthy hospital employees antibodies to SARS-CoV-2 could be determined and compared to participant sick leave records. Subjects with viral serum antibodies were not at excess risk for future sick leave (adjusted odds ratio (OR) controlling for age and sex: 0.85 [95% confidence interval (CI) (0.85 (0.43–1.68)]. By contrast, subjects with antibodies had an excess risk for sick leave in the weeks prior to testing [adjusted OR in multivariate analysis: 3.34 (2.98–3.74)]. Thus, presence of viral antibodies marks past disease and protection against excess risk of future disease. Knowledge of whether exposed subjects have had disease in the past or are at risk for future disease is essential for planning of control measures. Trial registration: First registered on 02/06/20, ClinicalTrials.gov NCT04411576.
format	article
author	Joakim Dillner K. Miriam Elfström Jonas Blomqvist Carina Eklund Camilla Lagheden Sara Nordqvist-Kleppe Cecilia Hellström Jennie Olofsson Eni Andersson August Jernbom Falk Sofia Bergström Emilie Hultin Elisa Pin Anna Månberg Peter Nilsson My Hedhammar Sophia Hober Johan Mattsson Laila Sara Arroyo Mühr Kalle Conneryd Lundgren
author_facet	Joakim Dillner K. Miriam Elfström Jonas Blomqvist Carina Eklund Camilla Lagheden Sara Nordqvist-Kleppe Cecilia Hellström Jennie Olofsson Eni Andersson August Jernbom Falk Sofia Bergström Emilie Hultin Elisa Pin Anna Månberg Peter Nilsson My Hedhammar Sophia Hober Johan Mattsson Laila Sara Arroyo Mühr Kalle Conneryd Lundgren
author_sort	Joakim Dillner
title	Antibodies to SARS-CoV-2 and risk of past or future sick leave
title_short	Antibodies to SARS-CoV-2 and risk of past or future sick leave
title_full	Antibodies to SARS-CoV-2 and risk of past or future sick leave
title_fullStr	Antibodies to SARS-CoV-2 and risk of past or future sick leave
title_full_unstemmed	Antibodies to SARS-CoV-2 and risk of past or future sick leave
title_sort	antibodies to sars-cov-2 and risk of past or future sick leave
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a12aa03869c945dba2214b88c4d4805c
work_keys_str_mv	AT joakimdillner antibodiestosarscov2andriskofpastorfuturesickleave AT kmiriamelfstrom antibodiestosarscov2andriskofpastorfuturesickleave AT jonasblomqvist antibodiestosarscov2andriskofpastorfuturesickleave AT carinaeklund antibodiestosarscov2andriskofpastorfuturesickleave AT camillalagheden antibodiestosarscov2andriskofpastorfuturesickleave AT saranordqvistkleppe antibodiestosarscov2andriskofpastorfuturesickleave AT ceciliahellstrom antibodiestosarscov2andriskofpastorfuturesickleave AT jennieolofsson antibodiestosarscov2andriskofpastorfuturesickleave AT eniandersson antibodiestosarscov2andriskofpastorfuturesickleave AT augustjernbomfalk antibodiestosarscov2andriskofpastorfuturesickleave AT sofiabergstrom antibodiestosarscov2andriskofpastorfuturesickleave AT emiliehultin antibodiestosarscov2andriskofpastorfuturesickleave AT elisapin antibodiestosarscov2andriskofpastorfuturesickleave AT annamanberg antibodiestosarscov2andriskofpastorfuturesickleave AT peternilsson antibodiestosarscov2andriskofpastorfuturesickleave AT myhedhammar antibodiestosarscov2andriskofpastorfuturesickleave AT sophiahober antibodiestosarscov2andriskofpastorfuturesickleave AT johanmattsson antibodiestosarscov2andriskofpastorfuturesickleave AT lailasaraarroyomuhr antibodiestosarscov2andriskofpastorfuturesickleave AT kalleconnerydlundgren antibodiestosarscov2andriskofpastorfuturesickleave
_version_	1718392753280253952

Antibodies to SARS-CoV-2 and risk of past or future sick leave

Ejemplares similares